

# Independent auditor's report

To Heumann Pharma GmbH & Co. Generica KG, Nuremberg

## Opinion

We have audited the financial statements of Heumann Pharma GmbH & Co. Generica KG (the Company), which comprise the balance sheet as at March 31, 2020 and the income statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at March 31, 2020, and of its financial performance and its cash flows for the year then ended in accordance with the German Legally Required Accounting Principles.

## Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statement section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the annual financial statements in Germany, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the annual financial statements in accordance with the accounting policies, and for such internal control as management determines is necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

## Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial statements.

As part of our audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements present the underlying transactions and give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German Legally Required Accounting Principles.

We communicate with management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

This report was issued for information purposes to Heumann Pharma GmbH & Co. Generica KG and must not be used in any other context than to inform its ultimate shareholder Torrent Pharmaceuticals Ltd. and to support the ultimate shareholder in fulfilling its filing requirements under the Indian Companies Act. This report must not, in particular, be handed out to third parties or included in sales prospectuses or similar public documents or media. "Third parties" in these regulations are not Torrent Pharmaceuticals Ltd., Ahmedabad, India, and the Indian Registrar of Companies.

We have provided the services described above on behalf of Heumann Pharma GmbH & Co. Generica KG. We have carried out our engagement on the basis of the General Engagement Terms included in our engagement agreement dated as of January 1, 2017 (Appendix 2). By taking note of and using the information as contained in our report each recipient confirms to have taken note of the terms and conditions stipulated in the aforementioned General Engagement Terms (including the liability limitations specified in item No. 9 included therein) and acknowledges their validity in relation to us.

Nuremberg, April 27, 2020

KPMG AG  
Wirtschaftsprüfungsgesellschaft

Signiert von  
Holger Kelle  
am 29.04.2020

Dr. Kelle  
Wirtschaftsprüfer  
[German Public Auditor]

Signiert von  
Andreas Arndt  
am 29.04.2020

Arndt  
Wirtschaftsprüfer  
[German Public Auditor]

## Appendices

Balance Sheet as at March 31, 2020	Appendix 1.1
Income Statement for the period from April 01, 2019 to March 31, 2020	Appendix 1.2
Notes to financial statements as of and for the year ended March 31, 2020	Appendix 1.3
General Engagement Terms	Appendix 2

# Heumann Pharma GmbH & Co.

## Generica KG, Nuremberg

### Balance Sheet as at March 31, 2020

#### Assets

	3/31/2020		3/31/2019	
	EUR	EUR	EUR	EUR
<b>A. Fixed assets</b>				
<b>I. Intangible assets</b>				
1. Purchased franchises, industrial and similar rights and assets, and licenses in such rights and assets	4,614,439.89		5,555,463.12	
2. Prepayments	1,794,334.98	6,408,774.87	1,358,755.70	6,914,218.82
<b>II. Property, plant and equipment</b>				
1. Land, land rights and buildings including buildings on third-party lands	175,224.52		182,280.54	
2. Plant and machinery	338,389.18		391,982.91	
3. Other equipment, furniture and fixtures	680,283.08	1,193,896.78	724,874.73	1,299,138.18
		<b>7,602,671.65</b>		<b>8,213,357.00</b>
<b>B. Current financial assets</b>				
<b>I. Inventories</b>				
1. Raw materials, consumables and supplies	594,960.21		419,981.80	
2. Goods	33,785,429.14		25,042,352.85	
3. Prepayments	1,966,669.67	36,347,059.02	21,684,108.72	47,146,443.37
– thereof against affiliated companies				
EUR 1,966,669.67				
(prior year EUR 21,684,108.72) –				
<b>II. Receivables and other assets</b>				
1. Receivables from other investees and investors	22,855,810.46		22,429,846.67	
2. Receivables from affiliates	68,884,688.11		56,681,488.94	
3. Other assets	6,908,454.25	98,648,952.82	7,111,435.86	86,222,771.47
<b>III. Cash at banks</b>		22,622,672.47		18,701,909.10
		<b>157,618,684.31</b>		<b>152,071,123.94</b>
<b>C. Prepaid expenses</b>		<b>270,922.17</b>		<b>307,895.29</b>
<b>D. Deferred tax</b>		<b>3,024,768.30</b>		<b>2,106,000.00</b>
		<b>168,517,046.43</b>		<b>162,698,376.23</b>

**Equity and liabilities**

	3/31/2020	3/31/2019
	EUR	EUR
<b>A. Equity</b>		
I. Capital shares of the limited partners	11,000.00	11,000.00
II. Capital reserves	0.00	0.00
III. Profit carryforward/Loss carryforward	8,709,673.98	-2,833,816.13
IV. Loss/Profit as shown in the balance	-2,222,780.11	11,543,490.11
	<b>6,497,893.87</b>	<b>8,720,673.98</b>
<b>B. Provisions</b>		
1. Provisions for pensions and similar obligations	8,709,549.00	8,068,285.00
2. Tax provisions	6,535,805.10	9,146,602.00
3. Other provisions	102,807,877.88	97,900,295.97
	<b>118,053,231.98</b>	<b>115,115,182.97</b>
<b>C. Liabilities</b>		
1. Liabilities to other investees and investors	5,524,552.08	36,501,382.34
2. Liabilities to affiliates	38,210,159.36	2,151,093.65
3. Other Liabilities	231,209.14	210,043.29
– thereof for taxes EUR 115,419.80 (prior year EUR 111,927.03) –		
	<b>43,965,920.58</b>	<b>38,862,519.28</b>
	<b>168,517,046.43</b>	<b>162,698,376.23</b>

# Heumann Pharma GmbH & Co.

## Generica KG, Nuremberg

### Income Statement

for the period from April 01, 2019 to March 31, 2020

	2019/2020		2018/2019	
	EUR	EUR	EUR	EUR
1. Revenues		94,404,588.89		104,794,345.47
2. Other operating income		5,552,715.29		8,939,833.58
3. Cost of raw materials, consumables and supplies and of purchased merchandise		-54,778,584.09		-59,355,324.36
4. Personnel expenses				
a) Wages and salaries	-7,488,949.72		-6,644,690.78	
b) Social security, pension and other benefit costs	-1,209,086.81	-8,698,036.53	-1,010,737.65	-7,655,428.43
– thereof for old-age pensions EUR 118,269.84 (prior year EUR 158,855.06) –				
5. Amortization, depreciation and write-downs of intangible assets and property, plant and equipment		-1,316,982.32		-1,226,604.16
6. Other operating expenses		-26,860,342.06		-23,107,122.90
7. Other interest and similar income		2,104,749.20		1,094,763.52
– thereof from affiliates EUR 2,103,403.85 (prior year EUR 1,026,779.60) –				
8. Interest and similar expenses		-1,145,061.55		-1,051,119.19
– thereof to affiliates EUR 200,025.58 (prior year EUR 35,075.34) –				
– thereof expenses from discounting EUR 868,834.96 (prior year EUR 952,864.00) –				
9. Income taxes		-1,531,034.80		-3,433,743.81
<b>10. Profit after income tax</b>		<b>7,732,012.03</b>		<b>18,999,599.72</b>
11. Other taxes		45,207.86		45,056.19
<b>12. Net income</b>		<b>7,777,219.89</b>		<b>19,044,655.91</b>
13. Withdrawal of capital reserve		0.00		37,498,834.20
14. Dividend payment		-10,000,000.00		-45,000,000.00
– thereof advanced dividend EUR 10,000,000.00 (prior year EUR 45,000,000.00) –				
<b>15. Loss/Profit as shown in the balance</b>		<b>-2,222,780.11</b>		<b>11,543,490.11</b>

# Heumann Pharma GmbH & Co.

## Generica KG, Nuremberg

### Statement of changes in fixed assets for fiscal year 1st of April 2019 to 31st of March 2020

	Acquisition and production cost				
	1st of April 2019	Additions	Disposals	Reclassifications	31st of March 2020
	EUR	EUR	EUR	EUR	EUR
<b>I. Intangible assets</b>					
1. Acquired franchises, industrial and similar rights and assets, and licenses in such rights and assets	23,180,901.46	300,536.55	1,100,027.09	421,676.87	22,803,087.79
2. Prepayments	1,358,755.70	936,844.78	79,588.63	-421,676.87	1,794,334.98
	<b>24,539,657.16</b>	<b>1,237,381.33</b>	<b>1,179,615.72</b>	<b>0.00</b>	<b>24,597,422.77</b>
<b>II. Property, plant and equipment</b>					
1. Land, land rights and buildings, including buildings on third-party land	342,230.41	0.00	0.00	0.00	342,230.41
2. Plant and machinery	743,341.24	4,639.77	0.00	0.00	747,981.01
3. Other equipment, furniture and fixtures	1,092,022.31	76,584.83	0.00	0.00	1,168,607.14
	<b>2,177,593.96</b>	<b>81,224.60</b>	<b>0.00</b>	<b>0.00</b>	<b>2,258,818.56</b>
	<b>26,717,251.12</b>	<b>1,318,605.93</b>	<b>1,179,615.72</b>	<b>0.00</b>	<b>26,856,241.33</b>

1st of April 2019	Accumulated depreciation		31st of March 2020	Net book values	
	Additions	Disposals		31st of March 2020	31st of March 2019
EUR	EUR	EUR	EUR	EUR	EUR
17,625,438.34	1,130,516.32	567,306.76	18,188,647.90	4,614,439.89	5,555,463.12
0.00	0.00	0.00	0.00	1,794,334.98	1,358,755.70
<b>17,625,438.34</b>	<b>1,130,516.32</b>	<b>567,306.76</b>	<b>18,188,647.90</b>	<b>6,408,774.87</b>	<b>6,914,218.82</b>
159,949.87	7,056.02	0.00	167,005.89	175,224.52	182,280.54
351,358.33	58,233.50	0.00	409,591.83	338,389.18	391,982.91
367,147.58	121,176.48	0.00	488,324.06	680,283.08	724,874.73
<b>878,455.78</b>	<b>186,466.00</b>	<b>0.00</b>	<b>1,064,921.78</b>	<b>1,193,896.78</b>	<b>1,299,138.18</b>
<b>18,503,894.12</b>	<b>1,316,982.32</b>	<b>567,306.76</b>	<b>19,253,569.68</b>	<b>7,602,671.65</b>	<b>8,213,357.00</b>